These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30468097)

  • 21. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new approach to pharmaceutical pricing based on patients' willingness to pay.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F
    Trop Med Int Health; 2018 Dec; 23(12):1326-1331. PubMed ID: 30286256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International drug price comparisons: quality assessment.
    Machado M; O'Brodovich R; Krahn M; Einarson TR
    Rev Panam Salud Publica; 2011 Jan; 29(1):46-51. PubMed ID: 21390419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
    Franzen N; Ziegler A; Romagnoli G; Retèl VP; Offerman TJS; van Harten WH
    Cancer Res Commun; 2022 Jan; 2(1):49-57. PubMed ID: 36860697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.
    Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN
    JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data.
    Hanlon M; Zhang R
    Int Health; 2013 Mar; 5(1):58-63. PubMed ID: 24029847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pricing policy towards the sourcing of cheaper drugs in Cyprus.
    Merkur S; Mossialos E
    Health Policy; 2007 May; 81(2-3):368-75. PubMed ID: 16949176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
    Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
    Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Vokó Z; Akhras KS; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):15-6. PubMed ID: 26707267
    [No Abstract]   [Full Text] [Related]  

  • 34. Determinants of drug prices: a systematic review of comparison studies.
    Janssen Daalen JM; den Ambtman A; Van Houdenhoven M; van den Bemt BJF
    BMJ Open; 2021 Jul; 11(7):e046917. PubMed ID: 34266841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of branded prescription medicine prices in OECD countries.
    Kanavos PG; Vandoros S
    Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
    Mahlich J; Sindern J; Suppliet M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.